IgA nephropathy trials in Spain
12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
- Where
- Barcelona, Cadiz, Madrid
- Age
- 2 years to 18 years
- People
- 28 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07498335 - Phase 3Taking peopleA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Where
- Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Sevilla
- Age
- 18 years and over
- People
- 347 worldwide
- Run by
- Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00 - Phase 3Taking peopleA clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
- Where
- Barcelona, Girona, Madrid, Manises, Sevilla
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-519638-22-00 · EU 2024-519638-22-00 - Phase 2Taking peopleA Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
- Where
- Barcelona, Lleida, Manises, Murcia
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- argenx
See details and how to joinNCT07773727 · EU 2026-525638-43-00 - Phase 2Taking peopleA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Barcelona, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - Phase 2Taking peoplePhase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
- Where
- Barcelona, Madrid, Seville
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06989359 - Phase 3Taking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- A Coruña, Alcorcón, Barcelona, Cáceres, Getafe, Girona, Madrid, Sevilla, Zaragoza
- Age
- 18 years and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - Phase 3Taking peopleA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Barcelona, Pamplona, Salamanca
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 3Taking peopleOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Where
- Girona
- Age
- 18 years to 100 years
- People
- 220 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06858319 - Phase 3Taking peopleStudy of Ravulizumab in Pediatric Participants With Primary IgAN
- Where
- Almería, Barcelona, Esplugues de Llobregat, Sevilla
- Age
- 2 years to 18 years
- People
- 36 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00 - Phase 2Taking peopleStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Where
- Barcelona, Madrid, Sevilla
- Age
- 1 year to 17 years
- People
- 67 worldwide
- Run by
- Travere Therapeutics, Inc.
See details and how to joinNCT05003986 · EU 2023-505497-14-00 - Phase 2/3Enrolling by invitationTrial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- Where
- Barcelona, Córdoba, Ellenboro, Madrid, Seville
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659